Emma Plested
Programme and Regulatory Affairs Director (UK)
Emma Plested is a Programme and Regulatory Affairs Director (UK) for the Oxford Vaccine Group (OVG). Emma joined the group in January 2005 and is responsible for the oversight of the full UK portfolio of trials undertaken by OVG. Emma leads the Project Management team who are responsible for ensuring all projects are delivered on time, within budget and in compliance with regulatory requirements.
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
The ‘Be on the TEAM’ Study (Teenagers Against Meningitis): Protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
Journal article
MAIDEN MCJ. et al, (2020), BMJ Open
-
The immunogenicity of the U.K. group B meningococcal vaccine (4CMenB) schedule against group B and C meningococcal strains: outcomes of the Sched3 randomised clinical trial.
Journal article
Davis K. et al, (2020), Lancet Infectious Diseases